Eindhoven-based pioneering MedTech company, Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, is starting its next chapter at High Tech Campus Eindhoven. Cleanroom construction will begin soon at HTC 7, with full relocation set for September 2026.
From left: Xeltis team Ian Johns, Eliane Schutte, Felix Bindels, and from HTCE: Otto van den Boogaard, Elsbeth Smit and Rik Creemers
“This move marks an important milestone in Xeltis’ commercial strategy as we scale our clinical operations and advance our lead candidate, aXess, towards commercialization,” said CEO Eliane Schutte. “We look forward to becoming part of this fantastic high-tech and deep-tech ecosystem!”
Rik Creemers, Business Development Manager at HTCE: “We are delighted to welcome Xeltis to High Tech Campus Eindhoven and look forward to hosting them in one of our multi-tenant buildings. It has been a pleasure to collaborate on this journey, culminating in the realization of a tailor-made cleanroom designed to support their continued innovation and next phase of growth.”
Xeltis’ broad pipeline of transformative implants are developed using the Company’s Endogenous Tissue Restoration (ETR) platform technology which incorporates Nobel-prize winning breakthroughs in PFAS free polymer technology. Using supramolecular chemistry, the technology was first developed by Prof. Jean-Marie Lehn, a pioneer in supramolecular chemistry and co-winner of the 1987 Nobel Prize in Chemistry. He serves on the Scientific Advisory Board at Xeltis.
Xeltis is developing a new generation of transformative implants that enable the natural creation of living and long-lasting vessels. Its proprietary ETR platform uses advanced supramolecular polymer materials electrospun into microfibres to create conduits, which regenerate the patient’s own tissue before gradually being absorbed and leaving living and long lasting vessels in place.
Xeltis is an international business with its roots in the Netherlands and clinical operations throughout Europe and the US
The company is backed by EQT Life Sciences, Invest-NL, Grand Pharma, DaVita Venture Group, the European Investment Bank (EIB), and the European Innovation Council (EIC).
Xeltis’ most advanced product under clinical development, aXess, is a vascular access conduit for patients with end-stage kidney disease requiring hemodialysis. In September 2025, Xeltis announced excellent clinical data from the aXess EU pivotal trial which is being conducted in 18 sites across the EU. Patient recruitment is well underway for the aXess US pivotal trial with interim results expected in 2026.
From left: Kirsten van de Ven, Rik Creemers, Felix Bindels, Eliane Schutte, Otto van den Boogaard, Ian Johns and Elsbeth Smit.
The move to HTCE comes at a pivotal moment for Xeltis as it prepares for the commercialization of aXess. As Ian Johns, Senior Director Operations at Xeltis, puts it: “High Tech Campus is the ideal location for the next phase in Xeltis’ growth. The team at HTCE truly understands our mission and has provided the space and technical environment we need to improve standards of care for millions of patients worldwide.”
For High Tech Campus Eindhoven, welcoming a company at this stage of development is exactly what the Campus is built for. “Xeltis is a strong addition to our MedTech community,” said Otto van den Boogaard, High Tech Campus CEO. “We look forward to supporting its journey from clinical trials to commercialization.”
HTCE continues to add technical space, such as clean rooms, and to renovate office space to accommodate growth of all Campus residents. Beyond this project, the Campus offers extensive opportunities for additional custom-built cleanroom solutions, enabling companies to scale and thrive in this innovative environment.
CUREON, the innovation center for MedTech and BioTech, opened at HTCE in October 2025, offering shared workspaces, labs and GMP-compliant clean rooms that help innovators bridge the gap between early research and market-ready healthcare solutions.
The Brainport region is a leading hub for MedTech and BioTech innovation, from precision systems to AI-driven diagnostics and smart biomaterials. HTCE sits at the heart of this ecosystem and hosts a thriving MedTech and BioTech cluster that grew from Philips and now includes more than 70 organizations. You can read more about it here.
High Tech Campus Eindhoven is a dynamic ecosystem where high-tech multinationals, SMEs, research institutes, service providers, scale-ups and startups work together on the technologies and products of tomorrow. HTCE currently houses over 300 leading high-tech companies and a vibrant community of 12,000 innovators, researchers and engineers. The Campus ecosystem stimulates collaboration and innovation, with expertise in electronics, integrated photonics, artificial intelligence, medical technology and sustainable energy. Multinationals such as Philips, Signify, NXP and ASML, as well as startups and scale-ups, contribute to groundbreaking technologies that shape the future.
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. Xeltis’ most advanced product currently under clinical development is aXessTM, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases.
Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors.
Visit the Xeltis website for more details: https://xeltis.com/